Compare FHTX & ECBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FHTX | ECBK |
|---|---|---|
| Founded | 2015 | 1919 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.4M | 182.5M |
| IPO Year | 2020 | 2022 |
| Metric | FHTX | ECBK |
|---|---|---|
| Price | $1.87 | $20.62 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $4.17 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 6.6K |
| Earning Date | 11-04-2026 | 10-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 25.32 | ★ 95.83 |
| EPS | N/A | ★ 0.77 |
| Revenue | ★ $30,909,000.00 | $598,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.98 | N/A |
| P/E Ratio | ★ N/A | $26.60 |
| Revenue Growth | ★ 36.75 | 3.64 |
| 52 Week Low | $1.79 | $14.83 |
| 52 Week High | $7.61 | $21.78 |
| Indicator | FHTX | ECBK |
|---|---|---|
| Relative Strength Index (RSI) | 15.02 | 43.79 |
| Support Level | $1.79 | $20.03 |
| Resistance Level | $5.35 | $20.79 |
| Average True Range (ATR) | 0.25 | 0.51 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 2.07 | 26.50 |
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
ECB Bancorp Inc operates as a bank holding company. The firm, through its subsidiary, engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, multifamily real estate loans, construction and land loans, and home equity lines of credit.